Implementation of pathogen-reduced platelets transfusion in a multidisciplinary clinic

The clinical efficacy of pathogen-reduced platelets transfusion was studied. 310 patients received 674 platelet transfusions, including 178 women (57.4%). Hematopoietic stem cell transplantation was received by 253 patients (81.6%). Bleeding was observed in 29 people (9.4%). Platelet transfusion allows to safely, without bleeding, overcome the period of cytopenia for oncohematological patients, recipients of hematopoietic stem cells. The introduction of intercept-pathogen-reduced platelets in the additive solution does not impair the effectiveness of hemostatic therapy and improves the logistics of platelet concentrates, which reduces the platelet count, which is an indication for prophylactic platelet transfusion.